Fresh Tracks Therapeutics, Inc. (FRTX)
(Delayed Data from OTC)
$0.88 USD
0.00 (0.00%)
Updated Aug 8, 2024 03:02 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FRTX 0.88 0.00(0.00%)
Will FRTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FRTX
Fresh Tracks Therapeutics (FRTX) Reports Q3 Loss, Tops Revenue Estimates
FRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for FRTX
Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company
Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
Clover Health Investments And 2 Other Stocks Under $1 Insiders Are Buying